

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen  
CVR number: 56759913

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail investor@lundbeck.com  
www.lundbeck.com



## Corporate Release

### **Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities**

**Valby, Denmark, 30 May 2016** - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by executives and persons and legal entities closely associated to them with shares and linked securities in Lundbeck, cf. Section 28a of the Danish Securities Trading Act.

Name:	Anders Gersel Pedersen
Job position:	Executive Vice President, member of the Executive Management
ID code (ISIN code):	DK 0010287234
Name of the issuer of the securities:	H. Lundbeck A/S
Description of the security:	Shares
Nature of the transaction:	Sale of shares
Date of trading:	27 May 2016
Market on which the trading was affected:	Nasdaq OMX Copenhagen
Number of traded securities:	45,000 shares
Total market price of securities traded:	DKK 11,718,109

Persons under obligation to report such transactions are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities could include but is not limited to:

- spouse or cohabitant
- children below the age of 18, provided that the executive is the custody holder
- legal entities in which the executive has a controlling influence

### **Lundbeck contacts**

Investors:

Palle Holm Olesen  
Vice President, Investor Relations  
palo@lundbeck.com  
+45 30 83 24 26

Media:

Mads Kronborg  
Senior Director, Corp. Communication  
mavk@lundbeck.com  
+45 36 43 30 00



### About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us on Twitter at @Lundbeck.